Nicotine nasal spray and vapor inhaler: Abuse liability assessment

Psychopharmacology

Volumn 130, Issue 4, 1997, Pages 352-361

  Schuh, Kory J ^a,c   Schuh, Leslie M ^b,c   Henningfield, Jack E ^b   Stitzer, Maxine L ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NIDA Addiction Research Center   (United States)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

abuse liability; humans; nasal spray; nicotine; plasma levels; smoking; subjective effects; vapor inhaler

Indexed keywords

NICOTINE; NOSE SPRAY;

ADULT; ARTICLE; CIGARETTE SMOKING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; FEMALE; HEART RATE; HUMAN; HUMAN EXPERIMENT; INHALATIONAL DRUG ADMINISTRATION; INHALER; INTRANASAL DRUG ADMINISTRATION; MALE; MOOD; NORMAL HUMAN; PRIORITY JOURNAL; RHINORRHEA; SINGLE BLIND PROCEDURE; SUBSTANCE ABUSE; THROAT DISEASE; VAPOR;

EID: 0030963524     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002130050250     Document Type: Article

References (38)

1. Balster RL, Schuster CR (1973) Fixed-interval schedule of cocaine reinforcement: effect of dose and infusion duration. J Exp Anal Behav 20:119-129
2. Benowitz NL, Henningfield JE (1994) Establishing a nicotine threshold for addiction. N Engl J Med 331:123-125
3. Benowitz NL, Jacob P, Denaro C, Jenkins R (1991) Stable isotope studies of nicotine kinetics and bioavailability. Clin Pharmacol Ther 49:270-277
4. Bergstrom M, Nordberg A, Lunell E, Antoni O, Langstrom B (1995) Regional deposition of inhaled 11C-nicotine vapor in the human airway as visualized by positron emission tomography. Clin Pharmacol Ther 57:309-317
5. Butschky MF, Bailey D, Henningfield JE, Pickworth WB (1995) Smoking without nicotine delivery decreases withdrawal in 12-hour abstinent smokers. Pharmacol Biochem Behav 50:91-96
6. Centers for Disease Control (1994) Cigarette smoking among adults - United States, 1993. Morbidity Mortality Weekly Report 43:925-930
7. de Wit H, Zacny J (1995) Abuse potential of nicotine replacement therapies. Adverse effects. CNS Drugs 4:456-468
8. deWit H, Bodker B, Ambre J (1992) Rate of increase of plasma drug level influences subjective response in humans. Psychopharmacology 107:352-358
9. Doll R, Peto R, Wheatley K, Gray R, Sutherland I (1994) Mortality in relation to smoking: 40 years' observation on male British doctors. BMJ 309:901-910
10. Food and Drug Administration (1995) 21 CFR Part 801, et al. Regulations restricting the sale and distribution of cigarettes and smokeless tobacco products to protect children and adolescents; proposed rule analysis regarding FDA's jurisdiction over nicotine-containing cigarettes and smokeless tobacco products; notice. Federal Register, August 11, 1995 pp 41314-41787
11. Griffiths RR, Bigelow GE, Liebson I (1983) Differential effects of diazepam and pentobarbital on mood and behavior. Arch Gen Psychiatry 40:865-873
12. Haertzen CA (1974) An overview of Addiction Research Center Inventory Scales (ARCI): an appendix and manual of scales. US Government Printing Office, Washington, DC, pp 74-92
13. Haertzen CA, Kocher TR, Miyasato K (1983) Reinforcements from the first drug experience can predict later drug habits and/or addiction: results with coffee, cigarettes, alcohol, barbiturates, minor and major tranquilizers, stimulants, marijuana, hallucinogens, heroin, opiates and cocaine. Drug Alcohol Depend 11:147-165
14. Henningfield JE (1995) Nicotine medications for smoking cessation. N Engl J Med 333:1196-1203
15. Henningfield JE, Keenan RM (1993) Nicotine delivery kinetics and abuse liability. J Consult Clin Psychol 61:1-8
16. Henningfield JE, Kozlowski LT, Benowitz NL (1994) A proposal to develop meaningful labeling for cigarettes. JAMA 272: 312-314
17. Jasinski DR (1977) Assessment of the abuse potentiality of morphine-like drugs (methods used in man). In: Martin WR (ed) Handbook of experimental pharmacology. Springer Heidelberg, pp 197-258
18. Jasinski DR, Henningfield JE (1989) Human abuse liability assessment by measurement of subjective and physiological effects. In: Fischman MW, Mello NK (eds) Testing for abuse liability of drugs in humans. NIDA Research Monograph 92, US Department of Health and Human Services, Rockville, Md., pp 73-100
19. Johanson CE, Fischman MW (1989) The pharmacology of cocaine related to its abuse. Pharmacol Rev 41:3-52
20. Leischow SJ (1994) The nicotine vaporizer. Health Values 18: 4-9
21. McNair DM, Lorr M, Droppleman LF (1971) EITS manual for the profile of mood states. Educational and Industrial Testing Service, San Diego, Calif.
22. Martin WR, Sloan JW, Sapira JD, Jasinski DR (1971) Physiological, subjective and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man. Clin Pharmacol Ther 12:245-258
23. Molander L, Lunell E, Andersson S-B, Kuylenstierna F (1996) Dose released and absolute bioavailability of nicotine from a nicotine vapor inhaler. Clin Pharmacol Ther 59:394-400
24. Perkins KA, Grobe JE, Stiller RL, Fonte C, Goettler JE (1992) Nasal spray nicotine replacement suppresses cigarette smoking behavior and desire. Clin Pharmacol Ther 52:627-634
25. Peto R (1994) Smoking and death: the past 40 years and the next 40. BMJ 309:937-939
26. Pomerleau OF, Flessland KA, Pomerleau CS, Hariharan M (1992) Controlled dosing of nicotine via an intranasal nicotine aerosol delivery device (INADD). Psychopharmacology 108:519-526
27. Pomerleau OF, Collins AC, Shiffman S, Pomerleau CS (1993) Why some people smoke and others do not: new perspectives. J Consult Clin Psychol 61:723-731
28. Rose JE, Levin ED (1991) Inter-relationships between conditioned and primary reinforcement in the maintenance of cigarette smoking. Br J Addict 86:605-609
29. Russell MAH (1991) The future of nicotine replacement. Br J Addict 86:653-658
30. Russell MAH, Jarvis MJ, Sutherland G, Feyerabend C (1987) Nicotine replacement in smoking cessation, absorption of nicotine vapor from smoke-free cigarettes. JAMA 257: 3262-3265
31. Schneider NG, Lunell E, Olmstead RE, Fagerstrom K (1996) Clinical pharmacokinetics of nasal nicotine delivery. Clin Pharmacokinet 31:65-80
32. Sutherland G, Russell MAH, Stapleton J, Feyerabend C, Ferno O (1992a) Nasal nicotine spray: a rapid nicotine delivery system. Psychopharmacology 108: 512-518
33. Sutherland G, Stapleton JA, Russell MAH, Jarvis MJ, Hajek P, Belcher M, Feyerabend C (1992b) Randomised controlled trial of nasal nicotine spray in smoking cessation. Lancet 340:324-329
34. Thorne DR, Genser SG, Sing HC, Hegge FW (1985) The Walter Reed performance assessment battery. Neurobehav Toxicol Teratol 7:415-418
35. Tonnesen P (1994) Nicotine vaporiser in smoking cessation. J Smoking-Related Disord 5:203-207
36. Tonnesen P, Norregaard J, Mikkelsen K, Jorgensen S, Nilsson F (1993) A double-blind trial of a nicotine inhaler for smoking cessation. JAMA 269:1268-1271
37. US Department of Health and Human Services (US DHHS) (1988) The health consequences of smoking: nicotine addiction. A Report of the Surgeon General. US Government Printing Office, Washington, D.C.
38. US Department of Health and Human Services (US DHHS) (1996) Clinical practice guideline, number 18. Smoking cessation. US Government Printing Office, Washington, D.C.